<DOC>
	<DOCNO>NCT00005977</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient non-Hodgkin 's lymphoma acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Non-Hodgkin 's Lymphoma Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine increase methotrexate dose combination standard treatment feasible patient advance small noncleaved cell non-Hodgkin 's lymphoma B-cell acute lymphocytic leukemia . - Assess toxicity intensify therapy patient . - Assess feasibility treat patient CNS disease diagnosis intensify therapy plus etoposide ifosfamide . - Assess toxicity late effect intensive therapy central nervous system , cardiac function , fertility patient . OUTLINE : This multicenter study . Patients stratify accord stage disease ( stage III non-Hodgkin 's lymphoma ( NHL ) v stage IV NHL CNS involvement v stage IV NHL CNS involvement v B-cell acute lymphocytic leukemia ( B-ALL ) CNS involvement v B-ALL CNS involvement ) . Patients receive methotrexate cytarabine intrathecally day 1 , 4 , 11 , 36 ( day 40 patient stage IV NHL B-ALL ) combination alternate course : A ) cyclophosphamide IV every 12 hour total six dos day 1-3 , doxorubicin IV 30 minute day 4 , vincristine IV day 4 11 , dexamethasone IV orally twice daily day 1-5 , filgrastim ( G-CSF ) subcutaneously ( SQ ) IV 30 minute begin day 5 continue blood count recover B ) methotrexate IV 24 hour day 18 , methotrexate intrathecally day 18 , dexamethasone IV orally twice daily day 18-22 , leucovorin calcium IV orally every 6 hour total 6 dos day 20-21 , cytarabine IV 48 hour day 20-21 , G-CSF SQ IV 30 minute begin day 22 continue blood count recover . Patients stage III NHL receive total 5 course treatment ( A-B-A-B-A ) patient stage IV NHL B-ALL CNS involvement receive total 6 course treatment ( A-B-A-B-A-B ) . Patients CNS involvement receive third course treatment : C ) etoposide IV 1 hour day 36-40 , ifosfamide IV 1 hour day 36-40 , oral dexamethasone twice daily day 36-40 , G-CSF SQ IV 30 minute begin day 41 continue blood count recover . Patients CNS involvement receive total 7 course treatment ( A-B-C-A-B-A-B ) . Patients follow every 6 month 4 year annually thereafter . PROJECTED ACCRUAL : A total 27-80 patient accrue study 24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically confirm small noncleaved cell nonHodgkin 's lymphoma Stage III IV Burkitt 's nonBurkitt 's Working Formulation OR Burkitt 's Burkitt'slike REAL classification Histologically confirm Bcell acute lymphocytic leukemia At least 25 % blast bone marrow FAB L3 morphology FAB L1 morphology allow blast show Bcell marker ( CD19 , 20 , 22 ) surface immunoglobulin positivity Must register POG9900 past 8 day PATIENT CHARACTERISTICS : Age : Under 22 time diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test HIV positive allow PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent use dexamethasone antiemetic Radiotherapy : Not specify Surgery : Prior surgery allow Other : No prior therapy except surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>L3 childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
</DOC>